BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Week in Review: Hutchison China MediTech (Chi-Med) Forms Drug Development JV With Nestle SA


12/3/2012 1:17:40 PM

by Richard Daverman, PhD

December 1, 2012 -- Hutchison Chi-Med and Nestlé formed a JV based on Chi-Med’s expertise in TCM, including Hutchison’s drug candidate for ulcerative colitis and Crohn’s disease; Crown Bioscience will join with Beijing Purunao Biotech to develop small molecule drugs aimed at oncology targets; Fosun Pharma and the Shanghai Institute of Materia Medica will jointly develop an innovative oncology drug; a 24% stake in China Pharmaceutical R&D Center Co. is up for sale at a price of $2.5 million; ChinaBio® recently completed a survey of 70 participants in the China healthcare sector, finding that they have grown more optimistic over the past year; AstraZeneca was given SFDA approval for Brilinta, a drug that fights blood clots, Qiagen won SFDA approval for its careHPV Test, an HPV test for remote areas; and TTY Biopharm, a Taiwanese drugmaker, opened its new $100 million drug manufacturing facility in Suzhou. More details….

Stock Symbols: (AIM: HCM) (SHA: 600196; HK: 2196) (NYSE: AZN) (NSDQ: QGEN)



Read at ChinaBio Today

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES